Holen Sie sich die Stockscreener-App
123.71
0.56%
0.60
Jazz Pharmaceuticals Plc Aktie (JAZZ) Neueste Nachrichten
Chart overlay techniques for tracking Jazz Pharmaceuticals plcMarket Sentiment Report & Reliable Price Action Trade Plans - Newser
Jazz Seeks Potential Expansion Of Epilepsy Franchise With Saniona Deal - insights.citeline.com
Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025 - WV News
Jazz pharmaceuticals acquires rights to Saniona’s epilepsy drug candidate By Investing.com - Investing.com Nigeria
Jazz Pharmaceuticals, Saniona Enter Exclusive Agreement - Contract Pharma
Why Jazz Pharmaceuticals (JAZZ) Is Up 5.2% After Modeyso Receives FDA Approval for Rare Brain Cancer - simplywall.st
Jazz pharmaceuticals acquires rights to Saniona’s epilepsy drug candidate - Investing.com
Jazz Pharmaceuticals licenses epilepsy drug from Saniona for $42.5M - StreetInsider
$1 Billion Deal: Jazz Pharma Secures Rights to Revolutionary Epilepsy Drug SAN2355 from Saniona - Stock Titan
Jazz Pharmaceuticals price target lowered to $165 from $166 at Morgan Stanley - MSN
Risk vs reward if holding onto Jazz Pharmaceuticals plcInflation Watch & Community Shared Stock Ideas - Newser
Has Jazz Pharmaceuticals plc formed a bullish divergenceMarket Rally & Free Risk Controlled Daily Trade Plans - Newser
Pattern recognition hints at Jazz Pharmaceuticals plc upsideJuly 2025 Pullbacks & Safe Entry Point Identification - Newser
Price action breakdown for Jazz Pharmaceuticals plcDollar Strength & Fast Moving Stock Trade Plans - Newser
Ligand to Participate in September Investor Conferences - GlobeNewswire Inc.
Using flow based indicators on Jazz Pharmaceuticals plcMarket Performance Summary & Low Risk High Win Rate Stock Picks - Newser
Jazz Pharmaceuticals plc Shows Early Signs of Technical Strength2025 Pullback Review & Expert Verified Movement Alerts - kangso.co.kr
Jazz Pharma gets FDA priority review for lung cancer therapy Zepzelca - MSN
AI Trend Models Suggest Bounce for Jazz Pharmaceuticals plcPortfolio Gains Report & Technical Pattern Based Buy Signals - 선데이타임즈
Will Jazz Pharmaceuticals plc bounce back from current supportMarket Growth Review & Low Drawdown Investment Ideas - Newser
AI Indicators Detect Buy Opportunity in Jazz Pharmaceuticals plcWeekly Trend Recap & AI Forecasted Entry and Exit Points - newsimpact.co.kr
Q2 Rundown: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Other Pharmaceuticals Stocks - Yahoo Finance
We Think Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Stay On Top Of Its Debt - 富途牛牛
Jazz Pharma wins FDA nod for Modeyso against rare brain tumor - MSN
Bollinger Band Squeeze Points to Volatility in Jazz Pharmaceuticals plc2025 Historical Comparison & Weekly Hot Stock Watchlists - classian.co.kr
Jazz Pharmaceuticals plc Approaches Psychological Resistance LevelEarnings Miss & Trade Opportunity Analysis Reports - sisa-n.com
Developing predictive dashboards with Jazz Pharmaceuticals plc dataMarket Activity Report & Reliable Volume Spike Alerts - Newser
Is Jazz Pharmaceuticals plc stock entering bullish territoryRate Hike & Low Risk Entry Point Tips - Newser
Using data tools to time your Jazz Pharmaceuticals plc exitExit Point & Reliable Price Breakout Alerts - Newser
Combining machine learning predictions for Jazz Pharmaceuticals plcWeekly Loss Report & Free Long-Term Investment Growth Plans - Newser
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Jazz Pharmaceuticals plc Earnings Report Breakdown: What Investors Should Know2025 Volatility Report & AI Powered Market Trend Analysis - Newser
Jazz Pharmaceuticals plc stock trend outlook and recovery pathPortfolio Return Summary & Verified Swing Trading Watchlists - Newser
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Published on: 2025-08-16 00:17:35 - thegnnews.com
BofA Securities raises Jazz Pharmaceuticals stock price target on Modeyso potential - Investing.com Nigeria
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Shares Bought by Charles Schwab Investment Management Inc. - Defense World
XTX Topco Ltd Acquires New Position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) - Defense World
United States Narcolepsy Drugs Market to Reach US$ 2,233.56 Million by 20337.88% CAGR Driven by Novel Therapies and Better Diagnosis - Yahoo Finance
JAZZ Q2 Deep Dive: Pipeline Milestones and Oncology Headwinds Shape Outlook - Yahoo Finance
Is FDA’s First-Ever Approval of Modeyso Shaping the Investment Case for Jazz Pharmaceuticals (JAZZ)? - simplywall.st
The 5 Most Interesting Analyst Questions From Jazz Pharmaceuticals’s Q2 Earnings Call - Yahoo Finance
PNC Financial Services Group Inc. Raises Stock Position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) - Defense World
How Jazz Pharmaceuticals plc stock performs during market volatilityShort-Term Stock Trend Forecast Guide - Newser
Cetera Investment Advisers Acquires 444 Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) - Defense World
Jazz Pharmaceuticals projects late Q4 zanidatamab Phase III data, signals leadership transition and updates 2025 guidance - MSN
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - simplywall.st
Mutual of America Capital Management LLC Has $3.86 Million Stock Holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) - Defense World
Avantax Advisory Services Inc. Lowers Stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) - Defense World
What data driven models say about Jazz Pharmaceuticals plc’s futureEntry Opportunity Screener with Confirmation - Newser
Jazz Pharmaceuticals gets EU nod for Ziihera - MSN
Don't Overlook Jazz (JAZZ) International Revenue Trends While Assessing the Stock - Yahoo Finance
FDA Grants Accelerated Approval to Dordaviprone For Diffuse Midline Glioma - Pharmacy Times
How to integrate Jazz Pharmaceuticals plc into portfolio analysis tools - Newser
Jazz’s Modeyso Approved For Rare Glioma With Expansion Targeted - insights.citeline.com
0.99%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):